Poland-based preclinical Contract Research Organisation Selvita SA (WSE: SLV) has completed the acquisition of Fidelta, also a contract research organisation, from Belgium-based Galapagos NV (Euronext &NASDAQ: GLPG), it was reported on Monday.
Selvita SA has acquired 100% of the outstanding shares in Fidelta. The deal is valued at EUR31.2m and the customary adjustments for net cash and working capital.
The acquisition should almost double Selvita's revenues. Fidelta will now be completely consolidated under the Selvita Group, but it will continue to operate under the Fidelta name.
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development